Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Sarcoma Clinical Trials

107 recruiting trials for Sarcoma. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
107
Total Trials
107
Recruiting Now
2
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT05366881

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer...

Sponsor: Adela, IncEnrolling: 700017 locations
RECRUITINGPhase 2NCT03935893

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

This is a Phase 2 study to evaluate the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in...

Sponsor: Udai KammulaEnrolling: 2401 location
RECRUITINGNCT06674811

Biomarkers of Resiliency In Childhood Cancer Surgery

This observational study is to better understand how children and their families recover after the stress of major surgery for cancer so that investigators can create ways to...

Sponsor: Mayo ClinicEnrolling: 401 location
RECRUITINGPhase 1 / Phase 2NCT07410676

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting...

Sponsor: Essen BiotechEnrolling: 831 location
RECRUITINGPhase 1NCT06889766

NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma

A single center, Phase I clinical trial to demonstrate safety and efficacy of LauT-1, autologous "New York Esophageal Squamous Cell Carcinoma-1 T-Cell Receptor (NY-ESO-1...

Sponsor: Centre Hospitalier Universitaire VaudoisEnrolling: 92 locations
RECRUITINGPhase 1NCT06942143

An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors

This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.

Sponsor: Guangzhou FineImmune Biotechnology Co., LTD.Enrolling: 151 location
RECRUITINGNCT05840575

Investigating Cognitive Impairment in Young Patients With Cancer Prospectively

The MyBrain study investigates the brain function of children, adolescents and young adults during and after chemo treatment for cancer. The tests include 1) cognitive skills such...

Sponsor: Rigshospitalet, DenmarkEnrolling: 1001 location
RECRUITINGPhase 1NCT06644755

First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.

Sponsor: Daiichi SankyoEnrolling: 1507 locations
RECRUITINGNCT06904365

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

Female patients with early onset (\<50 years old) pelvic malignancies such as uterine and rectal cancers are rising in incidence, which often requires pelvic radiation; many of...

Sponsor: Washington University School of MedicineEnrolling: 101 location
RECRUITINGPhase 1NCT07118176

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the...

Sponsor: Jonsson Comprehensive Cancer CenterEnrolling: 301 location
RECRUITINGNCT02012699

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal...

Sponsor: University of NebraskaEnrolling: 99999920 locations
RECRUITINGPhase 1 / Phase 2NCT03465592

Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

This research is being done to find out if an investigational drug, Nivolumab, can be safely administered after a "half-matched" (haplo) bone marrow transplant (BMT), and if the...

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsEnrolling: 394 locations
RECRUITINGNCT06004011

AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW)

Adolescents and young adults living with HIV experience higher premature mortality from cancer than their uninfected peers. In Zambia, because of multilevel barriers,...

Sponsor: ImplenomicsEnrolling: 41001 location
RECRUITINGNCT05539677

Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research

The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors...

Sponsor: N.N. Petrov National Medical Research Center of OncologyEnrolling: 10001 location
RECRUITINGPhase 1 / Phase 2NCT04577014

Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

This study is being done to find out whether the study drug Retifanlimab, a monoclonal antibody against the PD-1 protein, combined with gemcitabine and docetaxel, is a safe and...

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 981 location
RECRUITINGNCT02789384

CINSARC Signature and Correlation With Hemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study.

This is a prospective observational biomarker study including patients with non-metastatic, soft-tissue sarcomas (STS) for whom neoadjuvant chemotherapy is considered as the best...

Sponsor: Institut BergoniéEnrolling: 20510 locations
RECRUITINGNCT05108298

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

Sponsor: Eastern Cooperative Oncology GroupEnrolling: 40020 locations
RECRUITINGPhase 1 / Phase 2NCT04303117

PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

Background: Kaposi sarcoma (KS) tumors grow on the skin, lymph nodes, lungs, bone, and gastrointestinal tract. KS often affects people with immune deficiencies, such as among...

Sponsor: National Cancer Institute (NCI)Enrolling: 801 location
RECRUITINGPhase 2NCT06827717

Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing...

The current study is an investigator-initiated, single-arm phase 2 study that enrolled patients with recurrent and/or metastatic Ewing sarcoma for the treatment of Irinotecan...

Sponsor: Sun Yat-sen UniversityEnrolling: 291 location
RECRUITINGNCT04890067

Observational Study in Localized Osteosarcoma

Observational prospective trial aimed to collect the collect demographic, clinical, surgical, pathological and molecular characteristics and treatment from patients affected by...

Sponsor: Italian Sarcoma GroupEnrolling: 12016 locations
RECRUITINGPhase 2NCT05950594

IVIM & OLINK in Sarcoma

The hypoxia \> metastasis axis suggests that a DWI-based biomarker of hypoxia incorporating IVIM may be able to predict metastasis in STS patients, ultimately enabling...

Sponsor: University Health Network, TorontoEnrolling: 1451 location
RECRUITINGPhase 1NCT07194044

Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

This single arm study is designed to demonstrate the feasibility of a radically different approach for an exceptionally high-risk subset of MES with widely metastatic disease...

Sponsor: H. Lee Moffitt Cancer Center and Research InstituteEnrolling: 1517 locations
RECRUITINGPhase 1 / Phase 2NCT06094101

Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)

The PerVision trial utilizes an approach of a patient-individual cancer vaccine with sarcoma-specific peptides in metastasized fusion-driven sarcoma patients determined by next...

Sponsor: University Hospital TuebingenEnrolling: 304 locations
RECRUITINGNCT03967834

Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the...

This trial is a translational, open-label, multi-sites, prospective and retrospective cohort study of 500 patients aimed at clinical and biological characterization of sarcoma of...

Sponsor: Institut Claudius RegaudEnrolling: 40020 locations
RECRUITINGPhase 2NCT07089992

A Study of Pembrolizumab in People With Ultra-Rare Sarcomas

The purpose of the study is to find out if pembrolizumab is a useful treatment that causes few or mild side effects in people with ultra-rare sarcoma. The researchers will also...

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 326 locations
RECRUITINGPhase 2NCT05301283

Habitat Escalated Adaptive Therapy (HEAT), With Neoadjuvant Radiation for Soft Tissue Sarcoma

The purpose of the study is to utilize radiomic images to precisely locate areas of tumor that can be treated with dose escalation radiation therapy.

Sponsor: H. Lee Moffitt Cancer Center and Research InstituteEnrolling: 431 location
RECRUITINGPhase 2NCT06114225

Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body...

The aim of this study is to evaluate the efficacy and safety of pre-operative concurrent Stereotactic Body Radiotherapy (SBRT) and and programmed cell death protein-1 (PD-1)...

Sponsor: Ruijin HospitalEnrolling: 431 location
RECRUITINGNCT07470008

Prospective Registry of Histotripsy for Soft Tissue Tumors

Histotripsy is a treatment that uses focused ultrasound waves to break down tissue without surgery. The ultrasound waves meet at a specific spot and turn the tissue into liquid....

Sponsor: University of California, San FranciscoEnrolling: 2001 location
RECRUITINGNCT06760221

Safety and Efficacy of Preoperative SBRT and Radical Surgery for Soft Tissue Sarcoma of Extremities

Currently, the effectiveness and safety of preoperative hypo-fractionated radiotherapy in treating extremity soft tissue sarcomas remain inconclusive, warranting further...

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang UniversityEnrolling: 201 location
RECRUITINGPhase 1NCT04897321

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered...

Sponsor: St. Jude Children's Research HospitalEnrolling: 321 location
RECRUITINGPhase 2NCT06571734

XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma

This phase II trial tests how well zanzalintinib (XL092) works in treating patients with leiomyosarcoma that has spread from where it first started to other places in the body...

Sponsor: Northwestern UniversityEnrolling: 291 location
RECRUITINGNCT02792270

Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

This study is being conducted to decrease the rate of surgical wound complications. The investigators are studying the effects that caloric restriction has on decreasing the rate...

Sponsor: Massachusetts General HospitalEnrolling: 321 location
RECRUITINGPhase 1NCT06830031

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

This study is to investigate the safety and tolerability of C402-CD19-CAR treatment in subjects with relapsed or refractory large B-cell lymphoma and further determine the...

Sponsor: Shanghai Exuma Biotechnology Ltd.Enrolling: 181 location
RECRUITINGPhase 2NCT07359053

MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma

What is this study about? This is a medical research study testing a new drug combination ("Paclitaxel Polymer Micelles" + "Gemcitabine" + "Targeted Therapy") for patients with...

Sponsor: Shanghai 6th People's HospitalEnrolling: 461 location
RECRUITINGPhase 2NCT07193550

A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)

To study the treatment efficacy of zanzalintinib monotherapy in patients with advanced and/or metastatic bone sarcomas.

Sponsor: M.D. Anderson Cancer CenterEnrolling: 701 location
RECRUITINGNCT06073067

GRID Therapy for Extremity Soft Tissue Sarcoma

Patients with extremity soft tissue sarcoma (STS) are at high risk of recurrence. Pre-operative radiotherapy is used to increase the safe removal of tumors and improve local...

Sponsor: UNC Lineberger Comprehensive Cancer CenterEnrolling: 201 location
RECRUITINGPhase 1 / Phase 2NCT06327477

Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed...

This phase I/II trial studies the side effects and best dose of proton-spatially fractionated radiotherapy (P-SFRT) and to see how well it works with standard radiation therapy in...

Sponsor: Northwestern UniversityEnrolling: 281 location
RECRUITINGNCT05653388

Metastatic Leiomyosarcoma Biomarker Protocol

Leiomyosarcoma (LMS) is one of the most prevalent soft tissue sarcomas (STS) and can occur in various sites including soft tissue, uterus and retroperitoneal large vessels....

Sponsor: University of Michigan Rogel Cancer CenterEnrolling: 20011 locations
RECRUITINGPhase 2NCT07291297

Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced...

The purpose of this research study is to see how metformin, when used in combination with standard of care (SOC) treatment for metastatic (cancer that has spread) soft tissue...

Sponsor: Wake Forest University Health SciencesEnrolling: 502 locations
RECRUITINGPhase 1 / Phase 2NCT04094610

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies...

Sponsor: Turning Point Therapeutics, Inc.Enrolling: 7520 locations
RECRUITINGEarly Phase 1NCT04541108

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

This is a multi-center, open-label Phase 0 Master Protocol designed to study the localized pharmacodynamics (PD) of anti-cancer therapies within the tumor microenvironment (TME)...

Sponsor: Presage BiosciencesEnrolling: 1512 locations
RECRUITINGPhase 2NCT06760819

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in...

Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers...

Sponsor: BayerEnrolling: 11120 locations
RECRUITINGPhase 1 / Phase 2NCT05407441

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

This research study involves a combination of three drugs given together as a possible treatment for malignant rhabdoid tumor, atypical teratoid rhabdoid tumor, epithelioid...

Sponsor: Susan Chi, MDEnrolling: 493 locations
RECRUITINGPhase 1 / Phase 2NCT05955105

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

This is a multicenter, open-label, phase Ib/IIa study. The first part of the study will evaluate the safety, tolerability and preliminary efficacy of ILB2109 and Toripalimab in...

Sponsor: Innolake BiopharmEnrolling: 2001 location
RECRUITINGPhase 2NCT06816771

Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory...

To evaluate the efficacy and safety of pazopanib combined with TGI/CIV chemotherapy in children and adolescents with recurrent or refractory rhabdomyosarcoma.

Sponsor: Shandong Cancer Hospital and InstituteEnrolling: 381 location
RECRUITINGPhase 1NCT06641908

Anti-GD2 ADC M3554 in Advanced Solid Tumors

The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue...

Sponsor: EMD Serono Research & Development Institute, Inc.Enrolling: 5211 locations
RECRUITINGNCT07112989

Development of Innovative Preclinical Ex Vivo Models for the Study of Sarcomas and Metastases From Solid Tumors

The goal of this observational study is to learn how tumor tissue and blood samples from patients with sarcomas or metastases can be used to create laboratory models that help...

Sponsor: Istituto Ortopedico RizzoliEnrolling: 1251 location
RECRUITINGPhase 1NCT05859074

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back...

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 567 locations
RECRUITINGNCT07058064

WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)

The purpose of this study is to find a cost effective cardiovascular (CV) surveillance of cancer survivors over long periods of time to prevent the risk of progression of heart...

Sponsor: Mayo ClinicEnrolling: 2501 location
RECRUITINGPhase 1NCT06474676

T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft...

To find a recommended dose of attIL2-TIL cell therapy that can be given to participant with either relapsed or metastatic sarcomas (has come back or spread to other parts of the...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 401 location

Showing 50 of 107 trials.Search all Sarcoma trials

Frequently Asked Questions

There are currently 107 clinical trials for Sarcoma, with 107 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Sarcoma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 2 Phase 3 trials for Sarcoma, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.